Cyient DLM Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w5jd2qn5nd2fejnhxy405dlf.pdf

Key Takeaways


Altek Acquisition & the U.S. Manufacturing Bet

Bodanapu: "We are one of the few, if not one of the only one EMS company in the world that has this capability, especially at our scale, which is essentially to do safety critical, highly reliable, highly complex engineering centric electronics from India, from the U.S."

Margin Walk & the Q4 Recovery Promise

Kulkarni: "As we get into Q4, I think the one large deal, which is slightly a drag on the margins, is going to ramp down significantly, right? And therefore, I think our margins will improve in Q4 and beyond. So, you will see substantial improvement in the margins for the Q4 quarter."

Organic Demand & the Order Book


The Pipeline: Large but Unconverted


Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Q4 margin improvementSubstantial margin improvement as large low-margin deal ramps down significantlyQ4 FY25
ECL provision reversalConservative credit-loss provision on domestic receivables to reverse upon collectionNext quarter (Q4 FY25)
Full-year marginCloser to flat year-on-yearFY25
Altek sustainable EBITDA marginClear line of sight to 10%Sustainable basis (no date)
DIO targetReduce from 129 days to 90–100 daysRoadmap (no date)
DSO targetReduce to 60–70 days from 76 daysNo date
30% CAGRHealthy number for mid-to-long term, but not a firm year-on-year guide; variability expectedMid-to-long term
Large deal conversionThree advanced-stage deals expected to impact FY26 and next two fiscal years; dependent on transfer programsFY26 and beyond
Client inventory recoveryDemand from the destocking client expected to returnComing quarters

Key Metrics

MetricQ3 FY25
Revenue (consolidated)₹444.2 cr, +38.4% YoY, includes Altek
Revenue (standalone)₹357.3 cr, +11.3% YoY
Adjusted EBITDA₹35.9 cr, margin 8.1%, lower by 109 bps YoY
Reported EBITDA~₹27.9 cr, ~₹8 cr lower than adjusted due to one-off M&A expenses
Adjusted PAT₹16.6 cr, margin 3.7%, de-growth of ~10% YoY
Reported PAT₹10.8 cr, after adjusting for M&A expenses
Order backlog (consolidated)₹2,142.9 cr, includes Altek backlog of ₹291.5 cr
Order backlog (standalone)~₹1,850 cr
Industrial revenue growth+47% YoY
Medical revenue growth+156% YoY
Box build growth+16% YoY
DSO76 days, improved QoQ and YoY
DIO129 days, elevated; target 90–100 days
Net working capital~120 days, improved from 127 days QoQ
Free cash flow₹47.8 cr, positive for the quarter
Geography mix (Rest of world)61%, post-Altek consolidation
Geography mix (India)39%, post-Altek consolidation
Altek EBITDA margin (annual basis)~10%, comparable to Cyient DLM at EBITDA level
Additional amortization from Altek acquisition~$1 mn per year
M&A one-off expenses₹8 cr, booked as exceptional item
IPO proceeds utilized₹135 cr so far; ~₹190 cr expected by year-end
Order backlog execution timeline18–24 months
New award to meaningful revenue timeline9–12 months